



Atty. Dkt. No. 018733-0967

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG et al.

Title: IMMUNOTHERAPY OF
AUTOIMMUNE DISORDERS
USING ANTI-CD22 ANTIBODIES

Appl. No.: 09/590,284

Filing Date: 06/09/2000

Examiner: J. Roark

Art Unit: 1644

AMENDMENT TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an amendment in the above-identified application.

☐ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

☐ Small Entity statement is enclosed.

☒ The fee required for additional claims is calculated below:

| | Claims as Amended | Previously Paid For | Extra Claims Present | Rate | Additional Claims Fee |
|--|-------------------------|------------------------|----------------------------|------------|--------------------------|
| Total Claims: | 38 | 36 | 2 | x \$18.00 | \$36.00 |
| Independents: | 2 | 3 | 0 | x \$84.00 | \$0.00 |
| First presentation of any Multiple Dependent Claims: | | | | + \$280.00 | \$0.00 |
| CLAIMS FEE TOTAL: | | | | | \$36.00 |

☒ Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG *et al.*

Title: IMMUNOTHERAPY OF
AUTOIMMUNE DISORDERS
USING ANTI-CD22
ANTIBODIES WHICH TARGET
B-CELLS

Appl. No.: 09/590,284

Filing Date: June 9, 2000

Examiner: J. Roark

Art Unit: 1644

ELECTION OF SPECIES

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the communication dated April 15, 2002, applicants now provide a more detailed election of species, as requested. In addition, applicants request entry into the record of the following new claims:

RECEIVED

In the claims

JUN 24 2002

37. (New) A method of treating multiple sclerosis, comprising administering to a subject with multiple sclerosis a therapeutic composition comprising a naked anti-CD20 antibody, a naked anti-CD22 antibody that binds with epitope B of the CD22 antigen, and a cytokine, wherein the two antibodies and the cytokine can be administered concurrently or in any order.

38. (New) A method according to claim 36, wherein the cytokine is IFN- β .

10/20/2002 10:00 AM RECEIVED

10/20/2002

10/20/2002

#15/A
gnd
6/27/02

